Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02021500 · ClinicalTrials.gov registry record

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

A clinical trial of Pancreatic Cancer, sponsored by Celgene.

Completed
Registry status
40
Enrollment target
20
Study locations

NCT02021500: Completed study of Pancreatic Cancer, sponsored by Celgene.

NCT02021500 is a study of Pancreatic Cancer that has completed, run by Celgene. The registered enrollment target is 40 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02021500, a study of Pancreatic Cancer, has completed, sponsored by Celgene.

COMPLETED
Registry status
40 participants
Enrollment target
20
Study locations

Study Summary

A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.

Primary Outcome

Number of participants who survive

Conditions Studied

Interventions

  • DRUG ABI-007

Study Locations (20)

Arizona

  • TGen Clinical Research Services - Scottsdale
  • Mayo Clinic - Scottsdale

Florida

  • Florida Cancer Specialists - Englewood
  • Florida Cancer Specialist - Tavares

Virginia

  • Fairfax-Northern Virginia Haematology-Oncology - Fairfax
  • Virginia Cancer Institute - Richmond

New South Wales

  • Macarthur Cancer Therapy Centre - Campbelltown
  • Prince of Wales Hospital - Randwick

California

  • Pacific Shores Medical Group - Long Beach

Colorado

  • University of Colorado Cancer Center - Aurora

Indiana

  • Indiana University - Indianapolis

Massachusetts

  • University of Massachusetts Memorial Medical Center - Worcester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-01-02
Est. Completion 2015-04-16
Celgene

308 total trials

What the finished NCT02021500 record still lists

NCT02021500 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABI-007 is the first listed.

NCT02021500 names 20 study sites across 16 states, led by Arizona, Florida, Virginia.

Frequently Asked Questions

What is clinical trial NCT02021500 about?

NCT02021500 is a clinical study titled "A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.". A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.

What is the current status of trial NCT02021500?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2014-01-02. Estimated completion is 2015-04-16.

What conditions does trial NCT02021500 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT02021500?

The interventions under investigation include: ABI-007 (DRUG).

Who is sponsoring clinical trial NCT02021500?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02021500 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02021500's enrollment target sits among peer trials

40 168th of 278 higher than 105 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02021500, the US trial registry maintained by the National Library of Medicine. NCT02021500 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.